Precigen, Inc. Hits New 52-Week High of $7.50, Up 323.53%

Precigen, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 7.50 on August 21, 2026. This achievement marks a remarkable 323.53% increase in the stock's performance over the past year, significantly outpacing the S&P 500's growth of 20.47% during the same period. With a market capitalization of USD 1,299 million, Precigen operates in a competitive industry characterized by innovation and rapid advancements. Despite its recent price surge, the company remains in a loss-making position, reflected in its negative price-to-earnings ratio and a return on equity of -512.71%. Additionally, Precigen has a debt-to-equity ratio of -0.17, indicating a unique financial structure within its industry. The stock's previous 52-week low was recorded at USD 3, highlighting the substantial growth it has experienced. As Precigen continues to navigate the complexities of the biotechnology landscape, its recent performance underscores its evolving market position.